Emergent BioSolutions Inc.
EBSNYSEHealthcare● Active
$8.22
+$0.15(+1.86%)
Market Cap$424121586
P/E Ratio—
52W High$14.06
52W Low$5.62
Emergent BioSolutions Inc. (EBS) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
EBS · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: Apr 30, 2026EPS Actual
$0.21
Est. -$0.25 · +184.0%
Revenue
$0.16B
Est. $0.14B · +7.7%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
Apr 30, 2026
After Market Close
▲ Beat EPS▲ Beat Revenue✓ 1-Quarter EPS Beat Streak
EBS reports quarterly as a NYSE-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Rev. $0.58B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
Rev. Est.$0.58B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 5, 2026 | -$0.09 | — | — | — | $0.18B | — |
| ▲ Q2 FY2026 | Apr 30, 2026 | -$0.25 | $0.21 | +184.0% | $0.16B | $0.14B | +7.7% |
| ▼ Q1 FY2026 | Feb 26, 2026 | $0.11 | -$0.43 | -490.9% | $0.15B | $0.22B | -31.6% |
| ▲ Q4 FY2025 | Oct 29, 2025 | -$0.12 | $1.06 | +983.3% | $0.23B | $0.22B | +6.3% |
| ▲ Q3 FY2025 | Aug 6, 2025 | -$0.26 | $0.16 | +161.5% | $0.14B | $0.20B | -30.8% |
| ▲ Q2 FY2025 | May 7, 2025 | $0.49 | $0.71 | +44.9% | $0.22B | $0.22B | +1.5% |
| ▲ Q1 FY2025 | Mar 3, 2025 | -$0.35 | $0.05 | +114.3% | $0.19B | $0.28B | -32.1% |
| ▲ Q4 FY2024 | Nov 6, 2024 | $0.49 | $1.37 | +179.6% | $0.29B | $0.26B | +13.4% |
Q3 FY2026
Aug 5, 2026
EPS Actual
—
EPS Est.
-$0.09
EPS Surpr.
—
Revenue
—
Q2 FY2026
Apr 30, 2026Beat
EPS Actual
$0.21
EPS Est.
-$0.25
EPS Surpr.
+184.0%
Revenue
$0.16B
Q1 FY2026
Feb 26, 2026Miss
EPS Actual
-$0.43
EPS Est.
$0.11
EPS Surpr.
-490.9%
Revenue
$0.15B
Q4 FY2025
Oct 29, 2025Beat
EPS Actual
$1.06
EPS Est.
-$0.12
EPS Surpr.
+983.3%
Revenue
$0.23B
Q3 FY2025
Aug 6, 2025Beat
EPS Actual
$0.16
EPS Est.
-$0.26
EPS Surpr.
+161.5%
Revenue
$0.14B
Q2 FY2025
May 7, 2025Beat
EPS Actual
$0.71
EPS Est.
$0.49
EPS Surpr.
+44.9%
Revenue
$0.22B
Q1 FY2025
Mar 3, 2025Beat
EPS Actual
$0.05
EPS Est.
-$0.35
EPS Surpr.
+114.3%
Revenue
$0.19B
Q4 FY2024
Nov 6, 2024Beat
EPS Actual
$1.37
EPS Est.
$0.49
EPS Surpr.
+179.6%
Revenue
$0.29B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $0.36 | $0.37 | $0.38 | 1 |
| Q3 FY2027 | $0.26 | $0.27 | $0.28 | 1 |
| Q2 FY2027 | $0.30 | $0.31 | $0.32 | 1 |
| Q1 FY2027 | $-0.04 | $-0.04 | $-0.04 | 1 |
| Q4 FY2026 | $0.10 | $0.10 | $0.10 | 1 |
| Q3 FY2026 | $0.13 | $0.14 | $0.14 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $0.2B | $0.2B | $0.2B | 1 |
| Q3 FY2027 | $0.2B | $0.2B | $0.2B | 1 |
| Q2 FY2027 | $0.2B | $0.2B | $0.2B | 1 |
| Q1 FY2027 | $0.2B | $0.2B | $0.2B | 1 |
| Q4 FY2026 | $0.2B | $0.2B | $0.2B | 1 |
| Q3 FY2026 | $0.2B | $0.2B | $0.2B | 2 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | Apr 30, 2026 | +184.0% | $7.99 | $8.23 | +3.00% |
| ▼ Q1 FY2026 | Feb 26, 2026 | -490.9% | $11.01 | $11.10 | +0.82% |
| ▲ Q4 FY2025 | Oct 29, 2025 | +983.3% | $9.47 | $9.40 | -0.74% |
| ▲ Q3 FY2025 | Aug 6, 2025 | +161.5% | $6.10 | $6.03 | -1.15% |
| ▲ Q2 FY2025 | May 7, 2025 | +44.9% | $4.79 | $4.74 | -1.04% |
| ▲ Q1 FY2025 | Mar 3, 2025 | +114.3% | $7.48 | $6.83 | -8.69% |
| ▲ Q4 FY2024 | Nov 6, 2024 | +179.6% | $8.96 | $9.20 | +2.68% |
| ▼ Q3 FY2024 | Aug 6, 2024 | -139.2% | $9.72 | $9.86 | +1.44% |
Q2 FY2026+3.00%
Report Date
Apr 30, 2026
EPS Beat/Miss
+184.0%
Price Before
$7.99
Price After
$8.23
Q1 FY2026+0.82%
Report Date
Feb 26, 2026
EPS Beat/Miss
-490.9%
Price Before
$11.01
Price After
$11.10
Q4 FY2025-0.74%
Report Date
Oct 29, 2025
EPS Beat/Miss
+983.3%
Price Before
$9.47
Price After
$9.40
Q3 FY2025-1.15%
Report Date
Aug 6, 2025
EPS Beat/Miss
+161.5%
Price Before
$6.10
Price After
$6.03
Q2 FY2025-1.04%
Report Date
May 7, 2025
EPS Beat/Miss
+44.9%
Price Before
$4.79
Price After
$4.74
Q1 FY2025-8.69%
Report Date
Mar 3, 2025
EPS Beat/Miss
+114.3%
Price Before
$7.48
Price After
$6.83
Q4 FY2024+2.68%
Report Date
Nov 6, 2024
EPS Beat/Miss
+179.6%
Price Before
$8.96
Price After
$9.20
Q3 FY2024+1.44%
Report Date
Aug 6, 2024
EPS Beat/Miss
-139.2%
Price Before
$9.72
Price After
$9.86
Avg Beat Reaction-0.99%
Avg Miss Reaction+1.13%
Beat Rate6 / 8 quarters
Largest Move-8.69% (Q1 FY2025)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: EBS ends December
Emergent BioSolutions Inc. (EBS) most recently reported earnings on April 30, 2026 for Q2 FY2026, posting EPS of $0.21 — beating the analyst consensus of $-0.25 by +184.0%. The next EBS earnings date is expected around September 1, 2026.
Each quarter, investors track EBS earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. EBS revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
EBS's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
EBS earnings · 5 questionsEmergent BioSolutions Inc.'s next earnings report is expected around September 1, 2026. EBS typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; EBS historically reports after market close (AMC).
EBS earnings datewhen is EBS earningsEBS next earnings datewhen does EBS report earningsEBS earnings calendar
▸ Source: FMP · Emergent BioSolutions Inc. SEC filings · US GAAP · Emergent BioSolutions Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026